Abstract
In this issue of Clinical Cancer Research , Rajendran et al. ([1][1]) have assessed the value of pretherapy fluoromisonidazole (FMISO) positron emission tomography (PET) imaging, an indicator of tissue hypoxia, in predicting survival of 73 patients with head and neck cancers. In this study, the
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.